医学
米兰标准
肝细胞癌
肝移植
肝硬化
切除术
外科
入射(几何)
移植
内科学
光学
物理
作者
Xu Feng Zhang,Feng Xue,Fabio Bagante,Francesca Ratti,Hugo P. Marques,Sílvia Silva,Olivier Soubrane,Vincent Lam,George A. Poultsides,Irinel Popescu,Răzvan Grigorie,Sorin Alexandrescu,Guillaume Martel,Aklile Workneh,Alfredo Guglielmi,Tom Hugh,Luca Aldrighetti,Yi Lv,Timothy M. Pawlik
标识
DOI:10.1007/s11605-021-05206-8
摘要
To identify the preoperative risk factors for prediction of non-transplantable recurrence (NTR) after tumor resection for early-stage hepatocellular carcinoma (HCC) to assist in patient selection relative to upfront liver resection (LR) versus liver transplantation (LT).Patients who underwent curative resection for transplantable HCC and chronic liver disease were identified from an international multi-institutional database. NTR was defined as recurrence beyond the Milan or UCSF criteria, and the preoperative risk factors of NTR were investigated.Among 293 patients with transplantable HCC within Milan criteria and 320 within UCSF criteria, 113 (38.6%) and 131 (40.9%) patients developed tumor recurrence, respectively. Among patients who recurred, NTR was present in 32 (28.3%) patients within Milan and 35 (26.7%) within UCSF criteria. When either Milan or UCSF criteria was adopted, three preoperative risk factors including liver cirrhosis, tumor size > 3 cm, and multiple lesions were consistently identified as risk factors associated with NTR after curative resection. By summing up the three factors, a scoring model was established and the incidence of NTR among patients with 0, 1 or ≥ 2 risk factors incrementally increased from 4.5%, 13.3% to 20.5% when Milan criteria was used, and from 4.5%, 12.4% to 33.9% when UCSF criteria was adopted. The model demonstrated very good discriminatory power on internal validation (n = 5,000) (c-index 0.689 for Milan criteria, and 0.715 for UCSF criteria).Whereas surgical resection may be optimal first-line treatment for patients with no or one risk factor, patients with ≥ 2 risk factors should be considered for upfront liver transplantation.
科研通智能强力驱动
Strongly Powered by AbleSci AI